Ponatinib displayed 79% tumor growth inhibition in the NCOA4-RET model (CR1520) and near complete regression in the CCDC6-RET model (CR2518; Figure 4A, 4B; Supplementary Table 1). This evidence concerns the gene NCOA4 and neoplasm.